Short Interest in Health Catalyst, Inc. (NASDAQ:HCAT) Decreases By 10.9%

Health Catalyst, Inc. (NASDAQ:HCAT) was the recipient of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 2,530,000 shares, a decrease of 10.9% from the October 31st total of 2,840,000 shares. Based on an average daily volume of 485,300 shares, the short-interest ratio is currently 5.2 days.

Insider Buying and Selling

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total transaction of $40,109.30. Following the completion of the sale, the chief operating officer now directly owns 129,690 shares in the company, valued at approximately $998,613. The trade was a 3.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 26,568 shares of company stock worth $203,405 in the last 90 days. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

A number of hedge funds have recently added to or reduced their stakes in HCAT. Franklin Resources Inc. increased its holdings in Health Catalyst by 5.8% during the 3rd quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock worth $857,000 after purchasing an additional 5,687 shares during the period. Geode Capital Management LLC raised its holdings in shares of Health Catalyst by 4.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock valued at $11,749,000 after purchasing an additional 66,896 shares in the last quarter. Zacks Investment Management lifted its position in shares of Health Catalyst by 6.7% during the 3rd quarter. Zacks Investment Management now owns 296,121 shares of the company’s stock worth $2,410,000 after purchasing an additional 18,677 shares during the last quarter. State Street Corp grew its stake in shares of Health Catalyst by 2.5% during the third quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after purchasing an additional 28,251 shares in the last quarter. Finally, Quadrature Capital Ltd acquired a new position in shares of Health Catalyst during the third quarter worth $84,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Stock Performance

Shares of HCAT traded up $0.19 during trading on Tuesday, reaching $9.02. 946,180 shares of the company traded hands, compared to its average volume of 496,222. Health Catalyst has a twelve month low of $5.42 and a twelve month high of $11.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The stock has a 50-day simple moving average of $8.12 and a 200-day simple moving average of $7.33.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.22) earnings per share. Equities analysts predict that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on HCAT shares. Citigroup increased their price objective on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. increased their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Evercore ISI boosted their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Stephens upped their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Finally, Royal Bank of Canada boosted their target price on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.79.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.